Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Gene / Target24 Peer-Reviewed Briefings
Cytokine & JAK-STAT Signaling
Interleukin, TNF-α, interferon, and Janus kinase signaling cascades in inflammation and autoimmunity.
Active Specialties:NeurologyOncologyImmunologyInfectious DiseasePulmonologyPharmacologyPsychiatryEndocrinology
This case highlights fulminant cerebellitis as a life-threatening presentation of anti-GABA A R encephalitis and underscores the... She later stabilized with radiographic improvement and meaningful neurologic recovery.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
The risk-benefit ratio observed in the DALY 2-EU study supports consideration of zamto-cel as a second-line standard treatment option for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation. However, there is no evidence from randomised controlled trials in patients ineligible for transplantation.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Together, these findings demonstrate that Zbtb44 is a key regulator of colonic inflammation, a role that could be exploited therapeutically. Mechanistically, Zbtb44 undergoes SUMOylation, which facilitates its interaction with a conserved SUMO-interacting motif in T-bet, enabling binding to the IFN-γ promoter and enhancer to restrain chronic IFN-γ production.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
RSV binding and neutralizing antibodies were transiently elevated following natural infection in older adults but waned to levels similar to RSV-negative participants by the next season's start. Vaccines that counter waning immunity are needed in this high-risk population.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Lower temperature and extreme cold events, particularly CCS, were associated with AECOPD onset. Symptom-onset timing may better capture temperature-related associations than admission timing.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
These results demonstrate that regulated PKA signaling is essential for tissue-protective ILC3s, while IL-23 drives aberrant PKA signaling to elicit intestinal inflammation. Overproduction of IL-23 was sufficient to reduce PRKAR1A in ILC3s and increase PKA signaling that provoked gut inflammation.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
In a recent issue of Nature, macrophages polarized to an inflammatory state were found to produce several chimeric RNAs through trans-splicing with consequences for the inflammatory response. Published in Immunity, these peer-reviewed immunology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Thus, cDC1-T cell interactions are central to PD-L1×4-1BB activity, with antigen cross-presentation, dendritic-cell licensing, and IL-12 and 4-1BB costimulation converging to promote antitumor immunity. Treated tumors exhibited increased infiltration and spatial proximity of cDC1s and activated CD8 + T cells.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
These findings highlight that FcRn blockers such as efgartigimod may have potential to simultaneously target autoimmune, inflammatory, and fibrotic features of SSc and highlight the potential of autoantibody-reducing therapies as disease-modifying approaches in SSc. A randomised, controlled Phase 2 trial with efgartigimod in SSc is currently ongoing.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In this nonrandomized clinical trial, a single dose of mivocabtagene autoleucel resulted in immunotherapy-free remissions with a consistent, well-tolerated safety profile, demonstrating a highly effective therapy in antibody-positive SPS with the potential for durable remissions. Long-term follow-up is ongoing.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Bronchiectasis is associated with a systemic neutrophil and endothelial (blood-vessel lining) inflammatory signature linked to disease severity and risk of severe exacerbations, alongside altered but functionally-responsive circulating neutrophils. Neutrophilic inflammation in the airways is associated with exacerbation risk in patients with bronchiectasis.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
1 min read·American Journal of Respiratory and Critical Care Medicine·
This study provides longitudinal clinical and immunological observations of blinatumomab treatment in anti-Mi-2-positive DM and refractory AAV. These exploratory findings support further evaluation of blinatumomab in autoimmune diseases.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Undernutrition before and at treatment initiation is a potentially modifiable determinant of post-treatment lung impairment, with systemic inflammation mediating part of the effect. Nutritional assessment belongs in routine tuberculosis care, and nutritional support should be tested to prevent lung-function impairment in tuberculosis survivors.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Serious TEAEs were reported for 10 patients, including eight patients with grade 3 or higher events (non-hematologic, 13.5% (5/37); hematologic, 13.5% (5/37)). RP2D was selected based on overall safety and tolerability as well as preliminary anti-tumor activity in Agni-01 Phase 1.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Further research should investigate the relationship between peripheral and central measures of these elements and their metabolism, and further explore the relevance of pro-oxidant stress to the neuropathology of schizophrenia. The changes in serum iron, rubidium and selenium discriminate between control individuals and TRS cases, and they were not affected by age or clozapine serum levels.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Elevated expression of several cytokines in the CSF of virologically suppressed PWH indicates persistent immune activity and supports the existence of a central nervous system (CNS) reservoir. Numerous cytokines showed favorable associations with NP data, including "proinflammatory" cytokines such as IL-6 and TNF-α and several chemotactic cytokines, whereas some "anti-inflammatory" cytokines such as IL-10 correlated positively with unfavorable neurodegenerative markers.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Similar to genetic inactivation of autophagy, overexpression of IL-1α in AMs conferred broad spectrum protection against S. aureus and IAV, suggesting a possible strategy to fine-tune immune responses to combat important respiratory infections. As a result, autophagy-deficient mice showed more efficient clearance of S. aureus along with reduced lung damage and inflammation.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
Twice-yearly depemokimab was well tolerated and demonstrated sustained efficacy (real-world effectiveness in the trial) over the 2-year SWIFT and AGILE period, supporting its long-term therapeutic benefit and safety profile. Depemokimab is the first ultra-long-acting biologic, with enhanced interleukin-5 binding affinity, high potency, and extended half-life, enabling twice-yearly dosing.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These findings identify metabolic control of translation as a fever-sensitive checkpoint and establish arginine supplementation as a tractable strategy to enhance CAR T cell efficacy (real-world effectiveness in the trial). This effect required mTOR-dependent recruitment of the eIF4F translation-initiation complex and downstream c-MYC-driven metabolic reprogramming.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In this real-world emulated multicentre clinical trial, bDMARDs showed comparable overall trajectories of short-term effectiveness and long-term treatment persistence in PsA. The identification of partially distinct response patterns may support a more individualised approach to bDMARD selection.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Initial Phase 2 results further corroborated the safety of invika and expanded its preliminary evidence of clinically meaningful anti-tumor activity in ICB-resistant solid tumors, supporting further evaluation in the ongoing Phase 2. . Invika selectively and potently expanded peripheral and intratumoral Vβ6/Vβ10 T cells, of a predominantly memory-like phenotype, dose-dependently, peaking at the OBDs.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Our findings establish a pharmacological strategy to generate IL-10 + B cells with therapeutic potential and identify microglia as critical targets for intercepting neuroinflammatory disease progression. The therapeutic effect of IL-10 + B cell transfer was abrogated in mice lacking IL-10 receptor expression in long-lived myeloid cells, pointing to microglia as targets of B cell-derived IL-10.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population. Chronic Pseudomonas aeruginosa airway colonization in bronchiectasis (BE) is associated with frequent exacerbations.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These findings identify a conserved placental stress-associated transcriptional program and suggest that stress and MIA affect shared neurodevelopmental pathways in opposing directions. Weighted gene co-expression analysis of fetal brains revealed that prenatal stress and MIA regulate overlapping DNA repair, synaptic, and translational networks in opposite directions, with stress promoting signatures of premature maturation and MIA driving replication stress.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
1 min read·Molecular Psychiatry·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”